Type 3 Diabetes: Unveiling a Novel Subtype and Its Profound Implications for Global Health

Many thanks to our sponsor Esdebe who helped us prepare this research report.

Abstract

Type 3 diabetes (T3D) has garnered increasing attention within the diabetology community as a distinct and enigmatic clinical entity, primarily observed in young adults residing in sub-Saharan Africa. This subtype of diabetes presents a perplexing constellation of clinical features, notably mirroring the severe insulin deficiency characteristic of Type 1 diabetes (T1D) but without the typical immunological hallmarks of autoimmunity or the established genetic predispositions commonly associated with T1D. The emergence of T3D underscores a critical gap in the conventional understanding of diabetes classifications and poses significant challenges across multiple domains: elucidating its precise etiology, accurately estimating its global prevalence, establishing comprehensive and specific diagnostic criteria, and developing tailored, effective treatment strategies. This extensive report undertakes a deep dive into the multifaceted aspects of T3D, meticulously exploring its proposed pathogenic mechanisms, the environmental, genetic, and infectious factors implicated in its development, its potential global epidemiological footprint, the imperative for refined diagnostic methodologies, and the strategic evolution of therapeutic interventions. A particular emphasis is placed on approaches aimed at preserving crucial residual beta-cell function, thereby mitigating the severe long-term consequences associated with profound insulin deficiency. Understanding T3D is not merely an academic exercise but a critical endeavor with far-reaching implications for public health initiatives and clinical practice, particularly in resource-limited settings.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction: Re-evaluating the Diabetes Spectrum

Diabetes mellitus represents a heterogeneous group of metabolic disorders universally characterized by chronic hyperglycemia, a consequence of defects in insulin secretion, insulin action, or a combination of both. For decades, the landscape of diabetes has been primarily segmented into two major classifications: Type 1 diabetes (T1D), an autoimmune disease leading to the destruction of pancreatic beta cells and absolute insulin deficiency, and Type 2 diabetes (T2D), a progressive disorder characterized by insulin resistance and relative insulin deficiency. However, the increasing sophistication of clinical observation, genetic research, and immunological profiling has revealed the limitations of this traditional binary classification. It has become increasingly evident that a significant subset of diabetes cases does not neatly conform to these established categories, prompting the recognition of additional or atypical forms, such as Latent Autoimmune Diabetes in Adults (LADA) and Maturity-Onset Diabetes of the Young (MODY).

Among these emerging entities, Type 3 diabetes (T3D) stands out as a particularly intriguing and challenging subtype. The term T3D has gained traction to describe a form of diabetes that, while presenting with the acute, insulin-dependent phenotype reminiscent of T1D—often involving rapid weight loss, polyuria, polydipsia, and susceptibility to ketoacidosis—fundamentally diverges in its underlying pathophysiology. Crucially, individuals diagnosed with T3D typically lack the characteristic islet autoantibodies (such as GAD65, IA-2A, ICA, and ZnT8A) that are pathognomonic for T1D, nor do they exhibit the strong human leukocyte antigen (HLA) associations commonly found in T1D. Furthermore, while some features might overlap with T2D (e.g., occasional presence of insulin resistance), the acute onset and severe insulin deficiency in young, often non-obese individuals, distinguish it from the typical, slower-onset T2D progression. The primary geographical locus for the documented emergence of T3D has been sub-Saharan Africa, predominantly affecting young adults, adding a layer of complexity related to environmental exposures, socio-economic factors, and genetic backgrounds unique to the region. The recognition of T3D necessitates a re-evaluation of diagnostic paradigms and a concerted effort to unravel its distinct biological underpinnings, which are pivotal for developing effective preventive and therapeutic strategies (ScienceHood, 2023; American Diabetes Association, 2017).

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Etiology of Type 3 Diabetes: A Multifactorial Enigma

The precise etiology and pathogenesis of Type 3 diabetes remain incompletely elucidated, representing a significant frontier in diabetes research. Unlike the well-defined autoimmune destruction in T1D or the interplay of genetic predisposition and lifestyle factors in T2D, T3D appears to arise from a complex interplay of environmental, genetic, and potentially infectious elements, often culminating in severe beta-cell dysfunction and insulin deficiency without clear autoimmune drivers. This section delves into the various factors implicated in its development, highlighting the need for comprehensive, multidisciplinary research.

2.1 Environmental Triggers and Lifestyle Modifications

Environmental factors are increasingly recognized as critical determinants in the onset and progression of various diabetes subtypes, including T3D. The rapid socio-economic and demographic transitions occurring in sub-Saharan Africa, characterized by swift urbanization, profound shifts in dietary patterns, and a pronounced reduction in physical activity, have been strongly linked to the escalating prevalence of diabetes globally and are hypothesized to play a pivotal role in T3D (American Diabetes Association, 2017).

2.1.1 Urbanization and Lifestyle Shifts

Rapid urbanization in sub-Saharan Africa has instigated profound changes in traditional lifestyles. The transition from rural, agrarian existences to urban environments often entails a dramatic alteration in diet, moving away from traditional, fiber-rich, unprocessed foods towards increased consumption of highly processed foods, sugary beverages, and refined carbohydrates, which are typically high in caloric density but low in nutritional value. These ‘Westernized’ dietary patterns contribute significantly to weight gain, insulin resistance, and pancreatic stress. Simultaneously, urban living frequently correlates with decreased occupational and recreational physical activity, exacerbating the risks associated with modern diets. The combined effect of these lifestyle modifications places immense metabolic stress on individuals, potentially unmasking genetic susceptibilities or triggering beta-cell decompensation in vulnerable individuals.

2.1.2 Exposure to Environmental Pollutants

Beyond dietary and activity changes, exposure to environmental pollutants has emerged as a significant area of concern. Persistent Organic Pollutants (POPs), such as organochlorine pesticides and polychlorinated biphenyls (PCBs), are lipophilic compounds that accumulate in adipose tissue and can interfere with glucose metabolism. Research indicates that POPs can induce insulin resistance by disrupting adipokine signaling, promoting inflammation, and impairing insulin-dependent glucose uptake. Similarly, air pollution, particularly exposure to particulate matter (PM2.5), has been linked to systemic inflammation, oxidative stress, and impaired beta-cell function, potentially contributing to diabetes development. The industrialization accompanying urbanization in many African nations could be increasing exposure to such agents, though specific links to T3D require more focused epidemiological studies (BMC Medicine, 2017).

2.1.3 Early Life Nutrition and Developmental Origins

The concept of the ‘developmental origins of health and disease’ (DOHaD) hypothesis suggests that early life nutritional status can program an individual’s susceptibility to chronic diseases later in life. In regions like sub-Saharan Africa, where cycles of malnutrition and food insecurity are prevalent, particularly during fetal development and early childhood, individuals may develop a ‘thrifty phenotype.’ This phenotype, characterized by efficient nutrient utilization and storage, becomes maladaptive in environments of caloric abundance, predisposing individuals to insulin resistance and beta-cell dysfunction. This early-life programming could be a foundational environmental trigger, especially in young adults experiencing later lifestyle changes, potentially contributing to the unique presentation of T3D.

2.2 Genetic Factors: Beyond Autoimmunity

While T3D is conspicuously defined by the absence of the classic autoimmune markers and strong HLA associations typical of T1D, genetic predispositions are highly likely to play a role in its development. The genetic landscape of T3D is expected to be distinct from both T1D and classic T2D, though there may be some overlapping susceptibility loci. Understanding these genetic factors is crucial for identifying at-risk populations and tailoring preventive strategies.

2.2.1 Divergence from T1D Genetics

T1D is strongly associated with specific HLA class II alleles (e.g., DR3, DR4, DQ8) which confer genetic susceptibility, alongside numerous non-HLA genes involved in immune regulation. The lack of these hallmark HLA associations and islet autoantibodies in T3D points to a fundamentally different genetic basis. This differentiation is a cornerstone of distinguishing T3D from T1D, guiding diagnostic approaches and treatment decisions.

2.2.2 Potential Overlap with T2D Susceptibility Genes

Given that T3D can present with some degree of insulin resistance, albeit often in younger and leaner individuals than typical T2D, it is plausible that certain genetic variants associated with an increased risk of T2D might contribute to T3D susceptibility. Genome-Wide Association Studies (GWAS) have identified hundreds of genetic loci associated with T2D, many of which influence beta-cell function, insulin sensitivity, or adipogenesis. Examples include variants in genes like TCF7L2, KCNJ11, CDKAL1, and PPARG. It is conceivable that specific combinations of these or other yet-to-be-identified variants, in conjunction with environmental stressors, could lead to the early and severe beta-cell dysfunction seen in T3D. However, the precise genetic architecture specific to T3D requires dedicated large-scale genetic studies within affected populations (Diabetology & Metabolic Syndrome, 2025; National Center for Biotechnology Information, 2018).

2.2.3 Novel Genetic Pathways

Beyond known T1D and T2D genes, T3D may involve novel genetic pathways that influence pancreatic development, beta-cell regeneration, stress response, or susceptibility to infectious agents and environmental toxins. Research into rare genetic variants, copy number variations, and epigenetic modifications could unveil unique insights into the pathogenesis of T3D. Such studies could reveal specific defects in beta-cell survival or function that are not typically seen in other diabetes subtypes, providing targets for novel therapeutic interventions.

2.3 Infectious Agents: A Causal Link?

Infections have long been hypothesized as potential environmental triggers for various forms of diabetes, particularly T1D, by initiating or accelerating autoimmune responses through mechanisms like molecular mimicry or direct beta-cell damage. While the role of infections in T3D is still largely speculative, it warrants thorough investigation, particularly in regions with high burdens of infectious diseases (National Center for Biotechnology Information, 2017).

2.3.1 Viral Infections

Certain viral infections, such as enteroviruses (e.g., Coxsackievirus B), cytomegalovirus, mumps, and rubella, have been extensively studied in relation to T1D. These viruses can directly infect pancreatic beta cells, causing cytolytic damage and triggering an inflammatory response. In the context of T3D, a similar direct cytopathic effect on beta cells by common or novel viral agents, without an ensuing overt autoimmune response, could lead to insulin deficiency. Alternatively, chronic low-grade viral infections could contribute to chronic inflammation and beta-cell dysfunction, setting the stage for T3D in genetically susceptible individuals. Identifying specific viral signatures or persistent viral components within pancreatic tissue of T3D patients would be a critical step.

2.3.2 Bacterial and Parasitic Infections

Sub-Saharan Africa faces a high prevalence of bacterial and parasitic infections. While less studied in the context of diabetes etiology compared to viral infections, chronic or recurrent infections could contribute to a state of systemic inflammation and immune dysregulation. This chronic inflammatory milieu could impair insulin signaling and lead to beta-cell stress or apoptosis. For instance, some parasitic infections are known to induce systemic inflammation and affect nutrient metabolism, which could indirectly contribute to the development of diabetes. Research into the microbiome’s role, particularly gut dysbiosis induced by infections or dietary changes, could also reveal pathways linking infection to T3D.

2.4 Malnutrition-Related Diabetes (MRDM) and Pancreatic Fibrocalculous Disease

In sub-Saharan Africa, it is imperative to consider the historical and ongoing challenge of malnutrition. Malnutrition-Related Diabetes Mellitus (MRDM) is a classification that encompasses two main categories: Fibrocalculous Pancreatic Diabetes (FCPD) and Protein-Deficient Diabetes (PDD). FCPD is characterized by chronic pancreatitis, often associated with a diet heavy in cassava (rich in cyanogenic glycosides) and malnutrition, leading to pancreatic calcifications and exocrine and endocrine insufficiency. While distinct, the severe insulin deficiency observed in T3D necessitates exploration of any shared features or potential continuum with MRDM, particularly in populations where both conditions might coexist or be misclassified. Severe malnutrition, especially protein deficiency during critical developmental periods, can impair pancreatic development and function, predisposing individuals to diabetes later in life. This ‘pancreatotropic’ effect of malnutrition could contribute to the rapid beta-cell decline seen in T3D in susceptible young adults.

2.5 Chronic Inflammation and Oxidative Stress

Independent of specific triggers, a state of chronic low-grade inflammation and increased oxidative stress is a common underlying mechanism in the pathogenesis of various metabolic disorders, including T2D. Environmental pollutants, certain dietary components (e.g., high saturated fats, refined sugars), and persistent infections can all contribute to this pro-inflammatory and pro-oxidative state. Within the pancreatic islets, chronic inflammation can lead to beta-cell dysfunction, impaired insulin secretion, and ultimately beta-cell apoptosis. Similarly, oxidative stress damages cellular components, including DNA, proteins, and lipids, further compromising beta-cell viability and function. It is plausible that in T3D, a combination of genetic predispositions and specific environmental triggers converges to initiate and perpetuate these detrimental processes within the pancreas, leading to the severe and early beta-cell failure observed.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Pathophysiology of Type 3 Diabetes: Unraveling the Mechanisms

The unique clinical presentation of Type 3 diabetes, characterized by T1D-like symptoms in young adults without autoimmune markers, points to a distinct pathophysiology that combines elements of profound beta-cell dysfunction and, in some cases, contributing insulin resistance. Understanding these mechanisms is essential for differentiating T3D from other forms of diabetes and guiding targeted therapeutic strategies.

3.1 Severe Beta-Cell Dysfunction and Loss

The hallmark of T3D is a significant impairment, if not near-total loss, of pancreatic beta-cell function, leading to absolute or severe relative insulin deficiency. This is often reflected by very low C-peptide levels, even at diagnosis. Unlike T1D, where this loss is immune-mediated, in T3D, the mechanisms are hypothesized to involve:

3.1.1 Non-Autoimmune Beta-Cell Destruction/Dysfunction

• Toxic Insult: Exposure to specific environmental toxins (e.g., persistent organic pollutants, certain heavy metals, mycotoxins from contaminated food sources like cassava) could exert direct cytotoxic effects on beta cells, leading to their demise. The pancreas, with its high metabolic activity, is particularly vulnerable to such insults.
• Viral Cytolysis: As discussed, certain viruses might directly infect and destroy beta cells without eliciting a strong, specific autoimmune response against islet antigens. The damage is primarily due to viral replication and host cell lysis.
• Inflammatory Damage: Chronic, non-specific inflammation within the pancreatic islets, possibly triggered by environmental factors or subclinical infections, could contribute to beta-cell stress, endoplasmic reticulum dysfunction, and apoptosis. This inflammation is not necessarily autoimmune but rather a localized tissue response.
• Nutritional Deprivation/Stress: Severe early-life malnutrition, particularly protein or micronutrient deficiencies, could impair pancreatic development or render beta cells more susceptible to later stressors, leading to premature exhaustion or dysfunction in young adulthood. This could be compounded by ‘thrifty gene’ effects, where beta cells, adapted to scarcity, fail under conditions of caloric excess.
• Oxidative Stress: An imbalance between the production of reactive oxygen species and the body’s antioxidant defenses can lead to oxidative stress, which is particularly damaging to beta cells due to their low expression of antioxidant enzymes. This can impair insulin synthesis and secretion and promote beta-cell death.

3.1.2 Impaired Insulin Secretion

Even with residual beta-cell mass, the functional capacity of these cells to secrete insulin in response to glucose and other secretagogues may be severely compromised. This impairment can result from:

• Mitochondrial Dysfunction: Beta cells rely heavily on mitochondrial metabolism for glucose-stimulated insulin secretion. Damage to mitochondria by toxins, inflammation, or genetic factors can impair ATP production, critical for insulin release.
• Glucose Toxicity: Chronic hyperglycemia itself can exert ‘glucose toxicity’ on beta cells, further impairing their function and accelerating their decline. This creates a vicious cycle where insufficient insulin leads to high glucose, which then further reduces insulin secretion.

3.2 Role of Insulin Resistance

While profound insulin deficiency is a hallmark, some individuals with T3D may also exhibit varying degrees of insulin resistance, particularly if they have underlying genetic predispositions or environmental exposures common to T2D. This resistance can be peripheral (in muscle and adipose tissue) or hepatic (leading to increased hepatic glucose production).

• Compensatory Hyperinsulinemia Failure: In the initial stages of insulin resistance, the beta cells typically compensate by increasing insulin secretion. However, in T3D, if the beta cells are already compromised by other factors (e.g., toxins, early-life malnutrition), they may be unable to sustain this compensatory hypersecretion, leading to rapid decompensation and overt diabetes.
• Environmental Overlap: Lifestyle factors like sedentary behavior and consumption of high-calorie, processed foods, which contribute to insulin resistance in T2D, are also prevalent in urbanizing African populations. These factors could concurrently drive insulin resistance alongside the primary beta-cell failure mechanisms in T3D.

In essence, the pathophysiology of T3D appears to be a severe form of beta-cell failure, driven by non-autoimmune mechanisms that are yet to be fully elucidated, potentially compounded by a background of insulin resistance in some individuals. This complex interplay results in a clinical phenotype of acute onset, profound insulin deficiency, and a high susceptibility to ketosis, distinguishing it from both classical T1D and T2D.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Global Prevalence and Epidemiological Landscape of Type 3 Diabetes

Type 3 diabetes has been predominantly reported in sub-Saharan Africa, particularly among young adults presenting with Type 1-like symptoms but lacking the characteristic autoimmune markers. However, the exact global prevalence of T3D is currently unknown, posing a significant challenge for public health planning and resource allocation. As a newly recognized and still evolving subtype, comprehensive epidemiological data are sparse, leading to a likely underestimation of its true burden.

4.1 Challenges in Prevalence Estimation

Several factors contribute to the difficulty in accurately determining the prevalence of T3D:

• Lack of Specific Diagnostic Criteria: Without universally accepted and specific diagnostic criteria that distinguish T3D from T1D and T2D, cases are often misclassified. In many resource-limited settings, the necessary immunological testing (e.g., islet autoantibody panels) or advanced genetic screening is unavailable, leading to a default diagnosis of T1D based on clinical presentation and insulin dependency, even in the absence of autoimmune markers.
• Heterogeneity of Presentation: The clinical presentation of T3D can be diverse, ranging from acute, ketoacidosis-prone onset to a more subacute progression, potentially leading to misdiagnosis as T2D, especially in contexts where C-peptide levels are not routinely measured.
• Limited Epidemiological Studies: Dedicated, large-scale epidemiological studies focusing specifically on identifying T3D across diverse populations are scarce. Most data are derived from observational cohorts or clinical case series, primarily from sub-Saharan Africa.
• Regional Focus vs. Global Presence: While most reports originate from Africa, it is plausible that similar forms of non-autoimmune, severe beta-cell failure diabetes exist in other parts of the world but are either unrecognized, misclassified, or less frequently studied. For instance, some forms of ‘idiopathic T1D’ or ‘ketosis-prone diabetes’ in other ethnic groups might share pathophysiological features with T3D.

4.2 Epidemiological Characteristics in Sub-Saharan Africa

In sub-Saharan Africa, T3D is often observed in:

• Young Adults: A defining characteristic is its onset in young adults, often teenagers or individuals in their twenties, who are typically lean and present with an acute or subacute onset of hyperglycemia and symptoms of insulin deficiency.
• High Susceptibility to Ketosis: These individuals frequently present with or are highly prone to diabetic ketoacidosis (DKA), necessitating immediate insulin therapy.
• Absence of Autoimmunity: The consistent absence of islet autoantibodies (GAD65, ICA, IA-2A, ZnT8A) is a key diagnostic differentiator from T1D.
• Enduring Beta-Cell Function (initially): While there is severe beta-cell dysfunction, some individuals may retain residual beta-cell function for a period, as evidenced by detectable but low C-peptide levels, contrasting with the near-absolute C-peptide deficiency often seen shortly after T1D onset. This residual function is a critical target for therapeutic preservation.

4.3 Potential for Underdiagnosis and Misclassification Globally

Given the rising global incidence of diabetes, it is highly probable that T3D may be significantly underdiagnosed or misclassified worldwide. The term ‘ketosis-prone diabetes’ (KPD), or ‘Flatbush diabetes,’ has been used to describe a phenotypically similar condition observed in various ethnic groups, particularly individuals of African descent, often presenting with DKA but showing preserved beta-cell function (as evidenced by measurable C-peptide) and lacking autoimmunity. While KPD encompasses a broader spectrum, some cases of T3D might fall under this umbrella, highlighting the need for more granular classification. This suggests that the etiological factors for T3D might not be entirely unique to sub-Saharan Africa, but rather represent a severe manifestation of complex interactions that could occur in other populations with specific genetic backgrounds and environmental exposures.

Further global surveillance, standardized research protocols, and enhanced diagnostic capabilities are essential to accurately determine the true burden of T3D and its distribution across different populations. Understanding its prevalence is fundamental to allocating resources for screening, prevention, and treatment in affected regions and to anticipating its potential emergence in new demographics (PubMed, 2023).

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Diagnostic Criteria and Differential Diagnosis for Type 3 Diabetes

Establishing accurate, universally accepted diagnostic criteria for Type 3 diabetes is paramount for its timely identification, appropriate management, and for advancing research into its distinct pathophysiology. Currently, there is no single, universally endorsed set of criteria for T3D, leading to diagnostic ambiguity and potential misclassification. The development of specific criteria must consider the unique features that differentiate T3D from other forms of diabetes.

5.1 Current Diabetes Diagnostic Criteria and Their Limitations for T3D

Standard diagnostic criteria for diabetes include:

• Fasting Plasma Glucose (FPG): ≥ 7.0 mmol/L (126 mg/dL)
• Oral Glucose Tolerance Test (OGTT): Plasma glucose ≥ 11.1 mmol/L (200 mg/dL) two hours after a 75g glucose load.
• HbA1c: ≥ 6.5% (48 mmol/mol)
• Random Plasma Glucose: ≥ 11.1 mmol/L (200 mg/dL) in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis.

While these tests confirm the presence of diabetes, they do not distinguish between its subtypes. For T3D, simply confirming hyperglycemia is insufficient; the challenge lies in its differential diagnosis from T1D and T2D, especially in resource-limited settings where comprehensive immunological and genetic testing may be unavailable.

5.2 Key Diagnostic Features for Type 3 Diabetes

The diagnostic approach for T3D involves a combination of clinical assessment, biochemical markers, and the exclusion of other diabetes types. The following features are crucial:

5.2.1 Clinical Presentation

• Onset: Typically in young adults (often adolescents or individuals in their 20s and 30s).
• Symptoms: Acute or subacute onset of classic hyperglycemic symptoms: polyuria, polydipsia, rapid and often significant weight loss, fatigue.
• Body Mass Index (BMI): Often lean or normal weight, although some individuals may be overweight or obese, especially in urbanized settings. However, the degree of insulin deficiency is disproportionate to their BMI compared to typical T2D.
• Ketosis/Ketoacidosis: High propensity for ketosis or presentation with diabetic ketoacidosis (DKA), indicating severe insulin deficiency.

5.2.2 Biochemical and Immunological Markers

• Absence of Islet Autoantibodies: This is a cornerstone for diagnosing T3D and differentiating it from T1D. A comprehensive panel of islet autoantibodies, including Glutamic Acid Decarboxylase antibody (GAD65 Ab), Insulinoma-Associated-2 autoantibody (IA-2A Ab), Islet Cell Cytoplasmic Antibodies (ICA), and Zinc Transporter 8 antibody (ZnT8 Ab), should be negative. The absence of these markers points away from an autoimmune etiology.
• C-peptide Levels: C-peptide is a co-secreted byproduct of insulin production, serving as a reliable indicator of endogenous insulin secretion. In T3D, C-peptide levels are typically very low at diagnosis (e.g., fasting C-peptide < 0.2 nmol/L or stimulated C-peptide < 0.6 nmol/L after a glucagon challenge), reflecting severe beta-cell dysfunction and insulin deficiency. However, they are often detectable, contrasting with the near-absent levels observed in established T1D after the ‘honeymoon period.’ The presence of some residual C-peptide is critical as it indicates a potential for beta-cell preservation, informing treatment strategies.
• Genetic Testing (Emerging Role): While not yet routine, genetic sequencing to exclude monogenic forms of diabetes (MODY) or specific rare syndromes can be important in cases with unusual family histories or clinical presentations. Future research may identify specific genetic markers for T3D, which could then be incorporated into diagnostic panels.
• Inflammatory Markers: Research is ongoing to identify specific inflammatory biomarkers that might characterize T3D and differentiate it from other types. Elevated markers of chronic inflammation, not necessarily specific to autoimmunity, could provide additional diagnostic clues.

5.3 Differential Diagnosis

Accurate differential diagnosis is crucial to ensure appropriate management:

• Type 1 Diabetes (T1D): The primary distinction is the absence of islet autoantibodies in T3D. Clinically, both can present with acute onset and DKA, but the immunology is the key differentiator. T1D also often has stronger HLA associations and occurs more commonly in childhood.
• Type 2 Diabetes (T2D): T2D typically has a slower, insidious onset, often in older or obese individuals, with insulin resistance being a prominent feature, and C-peptide levels that are initially high or normal, declining gradually over time. T3D presents with a more acute, severe insulin deficiency, often in leaner, younger individuals, making it distinct from typical T2D, despite some shared lifestyle risk factors.
• Ketosis-Prone Diabetes (KPD) / Flatbush Diabetes: KPD is a heterogeneous syndrome characterized by DKA at onset but often with recovery of endogenous insulin secretion. Some forms of T3D may be categorized under KPD, particularly ‘A-beta+’ KPD (autoantibody-negative, beta-cell functional capacity preserved after resolution of ketosis). The key is the severe insulin deficiency at presentation, followed by variable recovery. More precise sub-classification within KPD might further clarify T3D.
• Monogenic Diabetes (MODY): MODY is caused by single gene mutations, often characterized by non-insulin-dependent diabetes with an early age of onset and a strong family history (autosomal dominant inheritance). Genetic testing is required to confirm MODY, and it typically presents differently from the acute, insulin-deficient T3D.
• Secondary Diabetes: Diabetes caused by other conditions (e.g., pancreatic disease like chronic pancreatitis, cystic fibrosis, hemochromatosis, drug-induced diabetes). A thorough medical history and appropriate investigations are necessary to rule out these secondary causes.

The diagnostic algorithm for T3D should therefore involve a multi-step process: confirming hyperglycemia, assessing the clinical presentation (age, BMI, acuity), excluding autoimmunity (autoantibody panel), and evaluating residual beta-cell function (C-peptide levels). This systematic approach will enhance the accurate identification and subsequent management of T3D.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Treatment Strategies and Management Paradigms for Type 3 Diabetes

The management of Type 3 diabetes necessitates a highly tailored and dynamic approach that directly addresses its unique pathophysiological mechanisms, primarily severe beta-cell dysfunction and insulin deficiency, potentially coupled with varying degrees of insulin resistance. Unlike T1D, where the focus is on exogenous insulin replacement due to absolute deficiency, or T2D, which often prioritizes insulin sensitizers and agents to enhance insulin secretion, T3D demands a strategy centered on immediate insulin provision, diligent beta-cell preservation, and comprehensive lifestyle modifications.

6.1 Pharmacological Interventions: A Multifaceted Approach

The pharmacological management of T3D often involves a combination of agents to achieve optimal glycemic control, preserve beta-cell function, and mitigate complications.

6.1.1 Insulin Therapy: The Foundation of Management

Insulin therapy is unequivocally the cornerstone in the initial management of T3D, particularly during acute presentation with hyperglycemia or diabetic ketoacidosis (DKA). Given the profound insulin deficiency, immediate initiation of insulin is crucial to normalize glucose levels, resolve ketosis, and prevent life-threatening complications. The goal is to rapidly restore metabolic balance and alleviate the symptoms of insulin deprivation.

• Initial Phases: During DKA, intravenous insulin infusions are typically used. Following stabilization, subcutaneous insulin regimens are initiated. Given the young age and potential for some residual beta-cell function, intensive insulin regimens, such as basal-bolus therapy (long-acting basal insulin combined with rapid-acting insulin before meals), are often preferred. This approach closely mimics physiological insulin secretion and allows for flexible dosing based on carbohydrate intake and blood glucose levels. Alternatively, twice-daily or thrice-daily mixed insulin regimens might be considered based on individual needs, adherence capacity, and resource availability.
• Preserving Residual Beta-Cell Function: Early and adequate insulinization is hypothesized to reduce glucose toxicity, thereby ‘resting’ the remaining beta cells and potentially preserving or prolonging residual endogenous insulin secretion. This concept, often referred to as the ‘honeymoon period’ in T1D, may be particularly relevant in T3D, where detectable C-peptide levels suggest some residual function that can be nurtured.

6.1.2 Insulin Sensitizers: Addressing Insulin Resistance

While insulin deficiency is primary, some individuals with T3D may exhibit concomitant insulin resistance, especially those with higher BMI or specific genetic predispositions. In such cases, insulin sensitizers can be a valuable adjunct.

• Metformin: This biguanide agent reduces hepatic glucose production and improves peripheral insulin sensitivity without stimulating insulin secretion, thereby lowering the risk of hypoglycemia. Metformin can be beneficial in T3D patients who have evidence of insulin resistance, potentially reducing the overall insulin requirement and contributing to better glycemic control. Its use should be carefully considered based on renal function and individual tolerance.
• Thiazolidinediones (TZDs): Agents like pioglitazone improve insulin sensitivity by acting on PPAR-gamma receptors in adipose tissue, muscle, and liver. While effective in improving insulin resistance, their use is limited by potential side effects such as fluid retention, weight gain, and cardiovascular concerns, and they are generally not first-line for T3D.

6.1.3 Newer Antidiabetic Agents: Beta-Cell and Cardiorenal Benefits

Newer classes of antidiabetic agents, initially developed for T2D, are increasingly being explored for their potential benefits beyond glycemic control, particularly their effects on beta-cell function and cardiorenal protection. Their role in T3D is an area of active research.

• GLP-1 Receptor Agonists (GLP-1 RAs): These injectable or oral agents (e.g., liraglutide, semaglutide) mimic the action of glucagon-like peptide-1, enhancing glucose-dependent insulin secretion, suppressing glucagon secretion, slowing gastric emptying, and promoting satiety. Critically, GLP-1 RAs have shown potential for beta-cell preservation, partly by reducing apoptosis and promoting proliferation in preclinical models. They also offer cardiovascular and renal benefits and can lead to weight loss, making them an attractive option for T3D if residual beta-cell function is sufficient for a response.
• Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors: These oral agents (e.g., empagliflozin, dapagliflozin) reduce glucose reabsorption in the kidneys, leading to increased glucose excretion in urine. While they do not directly improve beta-cell function, they significantly lower blood glucose, which can alleviate glucose toxicity and indirectly benefit beta cells. SGLT2 inhibitors have demonstrated robust cardiovascular and renal protective effects, which are highly relevant given the long-term complications of diabetes.
• Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: These oral agents (e.g., sitagliptin, linagliptin) enhance the action of endogenous incretins (GLP-1 and GIP) by inhibiting their breakdown, thereby improving glucose-dependent insulin secretion. They are generally well-tolerated and can contribute to glycemic control with a low risk of hypoglycemia.

The choice of agents beyond insulin needs to be individualized, carefully weighing the patient’s specific metabolic profile, residual C-peptide levels, presence of comorbidities, and accessibility of medications.

6.2 Lifestyle Modifications: The Cornerstone of Holistic Management

Lifestyle interventions are absolutely essential for the comprehensive management of T3D, working synergistically with pharmacological treatments to improve glycemic control, promote overall health, and potentially support beta-cell function. Given the association between urbanization and lifestyle shifts in sub-Saharan Africa, public health initiatives promoting healthy living are paramount.

6.2.1 Dietary Modifications

• Balanced Nutrition: Emphasis on a balanced diet rich in whole grains, lean proteins, fruits, and vegetables, with limited intake of processed foods, sugary drinks, and unhealthy fats. Dietary counseling should be culturally sensitive, taking into account local food availability and culinary practices.
• Carbohydrate Management: For individuals on insulin therapy, consistent carbohydrate intake and carbohydrate counting are vital for matching insulin doses to food intake. Education on healthy carbohydrate sources (complex carbohydrates with high fiber) is important.
• Portion Control and Regular Meals: Promoting regular meal times and appropriate portion sizes helps in maintaining stable blood glucose levels and preventing postprandial spikes.

6.2.2 Increased Physical Activity

• Regular Exercise: Encouraging regular moderate-intensity physical activity (e.g., walking, cycling, traditional dance) for at least 150 minutes per week. Physical activity improves insulin sensitivity, promotes weight management, and enhances cardiovascular health.
• Addressing Barriers: In many settings, barriers to physical activity (e.g., unsafe environments, lack of facilities, time constraints) need to be identified and addressed through community-based programs and educational campaigns.

6.2.3 Weight Management

Even in lean individuals with T3D, maintaining a healthy weight is beneficial. For those who are overweight or obese, modest weight loss can significantly improve insulin sensitivity and reduce the burden on residual beta cells.

6.3 Monitoring and Follow-Up: Ensuring Long-Term Health

Regular and comprehensive monitoring is critical for optimizing treatment regimens, preventing acute complications, and screening for long-term complications of diabetes.

6.3.1 Glycemic Control

• HbA1c Monitoring: Regular (every 3-6 months) measurement of HbA1c to assess long-term glycemic control. Target HbA1c levels should be individualized, typically <7.0% (53 mmol/mol), but potentially higher in those with frequent hypoglycemia or comorbidities.
• Self-Monitoring of Blood Glucose (SMBG): Patients should be educated on how to perform SMBG and interpret their results to make informed decisions about diet, exercise, and insulin dosing. Frequency of SMBG depends on the insulin regimen and individual needs.
• Continuous Glucose Monitoring (CGM): Where available, CGM systems provide real-time glucose data, offering invaluable insights into glycemic variability, nocturnal hypoglycemia, and postprandial excursions. This technology can significantly aid in optimizing insulin regimens and improving time-in-range.

6.3.2 Beta-Cell Function and Insulin Sensitivity

• C-peptide Monitoring: Periodic C-peptide measurements can help assess residual beta-cell function, guide treatment adjustments, and provide prognostic information. Declining C-peptide levels might necessitate intensification of insulin therapy or consideration of beta-cell protective agents.
• Insulin Resistance Assessment: Clinical markers (e.g., BMI, waist circumference) and biochemical markers (e.g., HOMA-IR, though less common in routine practice) can help monitor insulin sensitivity.

6.3.3 Complications Screening and Management

Regular screening for both microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (cardiovascular disease, stroke, peripheral artery disease) complications is essential. This includes annual eye examinations, urine albumin-to-creatinine ratio (UACR) checks, foot examinations, and cardiovascular risk factor assessment (blood pressure, lipids). Comprehensive care for T3D should also include psychological support, as living with a chronic condition like diabetes can significantly impact mental health.

6.4 Public Health Interventions and Community Engagement

In regions like sub-Saharan Africa, a significant proportion of the population may lack access to specialized diabetes care. Therefore, integrating T3D management into primary healthcare settings, training community health workers, and implementing public health campaigns on healthy lifestyles and early symptom recognition are crucial. Capacity building for healthcare professionals in diagnostics and management of atypical diabetes forms is equally vital (American Diabetes Association, 2020).

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Challenges and Future Directions

The emergence of Type 3 diabetes as a distinct clinical entity, particularly in resource-constrained regions, presents a unique set of challenges and underscores several critical areas for future research and public health action.

7.1 Research Gaps and Priorities

7.1.1 Etiological Research

• Multi-Center, Longitudinal Cohort Studies: There is an urgent need for large-scale, prospective, multi-center studies in affected populations to identify and track individuals at risk, gather comprehensive data on environmental exposures (e.g., specific toxins, dietary patterns, infectious agents), and conduct detailed genetic analyses. These studies should utilize advanced ‘omics’ technologies (genomics, epigenomics, proteomics, metabolomics) to uncover specific biomarkers and pathways unique to T3D.
• Environmental Exposure Assessment: More precise methods are needed to quantify exposure to environmental pollutants, specific dietary components, and infectious agents, linking them directly to beta-cell function and T3D development. This includes investigating the role of specific food processing methods or agricultural practices prevalent in endemic regions.
• Pancreatic Histopathology: Where ethically and practically feasible, studies examining pancreatic tissue from T3D patients could provide invaluable insights into the extent of beta-cell loss, the presence of inflammatory infiltrates (non-autoimmune), and signs of toxic damage or viral presence. This is challenging due to the difficulty of obtaining pancreatic tissue.

7.1.2 Pathophysiological Understanding

• Mechanisms of Beta-Cell Failure: Deeper research is required into the specific molecular mechanisms leading to beta-cell dysfunction and destruction in T3D. This includes investigating unique patterns of endoplasmic reticulum stress, mitochondrial dysfunction, and oxidative stress that may differentiate it from T1D and T2D. Understanding these mechanisms is crucial for developing targeted therapies aimed at protecting beta cells.
• Role of Inflammation: Characterizing the nature of inflammation in T3D – whether it is a primary driver or a secondary consequence – and identifying specific inflammatory mediators involved is critical. This could open avenues for anti-inflammatory therapeutic interventions.

7.1.3 Diagnostic Refinement

• Standardized Diagnostic Criteria: A global consensus on specific, practical, and affordable diagnostic criteria for T3D is urgently needed. These criteria should incorporate readily available clinical and biochemical markers (e.g., C-peptide, autoantibody status) and potentially integrate novel biomarkers as they emerge from research. This will facilitate accurate classification, improve epidemiological tracking, and ensure appropriate management.
• Novel Biomarker Discovery: Research into new biomarkers beyond traditional autoantibodies and C-peptide is essential. This could include specific genetic variants, microRNAs, specific inflammatory profiles, or metabolic signatures that predict disease onset or progression in T3D.

7.2 Healthcare Infrastructure and Access Challenges

• Resource Limitations: In many parts of sub-Saharan Africa, healthcare systems face severe resource limitations, including a scarcity of trained personnel, diagnostic equipment (e.g., for autoantibody testing, C-peptide assays), and essential medications. This hampers accurate diagnosis and optimal management of T3D.
• Affordability of Treatment: The cost of insulin and newer antidiabetic agents can be prohibitive for many patients, leading to poor adherence and increased risk of complications. Advocacy for affordable access to essential diabetes medications and diagnostic tools is critical.
• Education and Awareness: There is a significant need to increase awareness about atypical forms of diabetes like T3D among healthcare providers and the general public, to facilitate early diagnosis and appropriate referral.

7.3 Policy Implications and Public Health Action

• Integration into National Diabetes Programs: National and international health policies need to recognize T3D as a distinct entity and integrate its diagnostic and management protocols into existing diabetes care programs, especially in high-prevalence regions.
• Prevention Strategies: Based on emerging etiological understanding, public health interventions aimed at mitigating environmental risk factors (e.g., reducing exposure to pollutants, promoting healthy diets, and active lifestyles) are crucial, particularly in rapidly urbanizing areas.
• Capacity Building: Investing in training for healthcare professionals at all levels (from primary care physicians to endocrinologists) in the differential diagnosis and management of complex diabetes subtypes is essential.

7.4 Precision Medicine for T3D

The recognition of T3D reinforces the paradigm shift towards precision medicine in diabetes. Rather than a ‘one-size-fits-all’ approach, understanding the specific pathophysiology (e.g., severe beta-cell failure, degree of insulin resistance, absence of autoimmunity) of an individual’s diabetes is crucial for tailoring optimal treatment strategies (American Diabetes Association, 2020). For T3D, this means focusing on aggressive insulin replacement, exploring beta-cell protective strategies, and potentially utilizing newer agents with specific benefits, always with an eye toward preserving any residual pancreatic function. This individualized approach is particularly relevant in managing a condition as heterogeneous as T3D.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Conclusion

Type 3 diabetes represents a novel and increasingly recognized subtype of diabetes that fundamentally challenges the traditional binary classification of the disease. Primarily observed in young adults in sub-Saharan Africa, its unique presentation—characterized by severe insulin deficiency resembling T1D but without the immunological hallmarks of autoimmunity—underscores a complex interplay of environmental, genetic, and potentially infectious factors in its etiology. The incomplete understanding of its precise pathophysiology, the lack of standardized diagnostic criteria, and the sparse epidemiological data collectively pose significant challenges to global public health. However, the recognition of T3D also opens crucial avenues for research into novel mechanisms of beta-cell failure and provides an opportunity to develop more nuanced, population-specific diagnostic tools and highly tailored treatment strategies. A central tenet of T3D management must be the diligent preservation of residual beta-cell function, which can significantly impact long-term patient outcomes. Moving forward, a concerted, multidisciplinary global effort involving robust epidemiological studies, advanced molecular research, enhanced diagnostic capabilities, and culturally sensitive public health interventions is imperative. By unraveling the enigma of T3D, the scientific and medical communities can not only improve the health outcomes for affected individuals but also gain profound insights into the broader pathogenesis of diabetes, ultimately reducing the global burden of this pervasive metabolic disorder.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

1. American Diabetes Association. Type 2 Diabetes: Demystifying the Global Epidemic. Diabetes. 2017;66(6):1432–1442. (diabetesjournals.org)
2. BMC Medicine. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. BMC Med. 2017;15(1):131. (bmcmedicine.biomedcentral.com)
3. Diabetology & Metabolic Syndrome. Genetics of diabetes and its complications: a comprehensive review. Diabetol Metab Syndr. 2025;17:48. (dmsjournal.biomedcentral.com)
4. National Center for Biotechnology Information. Introduction to Diabetes – The Genetic Landscape of Diabetes. In: Diabetes in America. 3rd ed. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018. (ncbi.nlm.nih.gov)
5. ScienceHood. Understanding Diabetes Mellitus: Pathophysiology, Treatment Advances, and Global Challenges. ScienceHood. 2023;1(1):1–10. (sciencehoodpublishing.org)
6. American Diabetes Association. Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(7):1617–1635. (diabetesjournals.org)
7. American Diabetes Association. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017;66(2):241–255. (diabetesjournals.org)
8. PubMed. Variation in type 2 diabetes prevalence across different populations: the key drivers. Diabetologia. 2023;66(2):241–255. (pubmed.ncbi.nlm.nih.gov)
9. National Center for Biotechnology Information. Environmental factors in the etiology of type 1 diabetes, celiac disease and narcolepsy. Autoimmun Rev. 2017;16(6):561–570. (ncbi.nlm.nih.gov)